Verrica Pharmaceuticals Inc. (VRCA)
| Market Cap | 373.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.69M |
| Shares Out | 25.00M |
| EPS (ttm) | -1.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 23 |
| Last Price | $13.53 |
| Previous Close | $13.80 |
| Change ($) | -0.27 |
| Change (%) | -1.96% |
| Day's Open | 13.91 |
| Day's Range | 13.26 - 13.67 |
| Day's Volume | 2,044 |
| 52-Week Range | 6.02 - 18.42 |
WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical intervent...
Torii to make upfront payment of $11.5 million to Verrica in addition to other potential milestone payments of up to $58 million and, if marketed in Japan, tiered transfer price payments as a percentage...
– FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 –
WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...
WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...
- PDUFA goal date assigned is June 23, 2021 -
- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline and new mol...
WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...
- Verrica reaffirms expectation to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - - Verrica reaffirms expectation to resubmit its New Drug App...
WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...
- 35 % of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2. 4 % for vehicle (p=0.0001) -
- Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 -
WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring med...
NEW YORK, Sept. 14, 2020 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc.
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action fi...
Los Angeles, California--(Newsfile Corp. - September 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharm...
New York, New York--(Newsfile Corp. - September 10, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
BENSALEM, Pa., Sept. 10, 2020 /PRNewswire/ -- Law Offices of Howard G.
Los Angeles, California--(Newsfile Corp. - September 10, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharm...
LOS ANGELES, Sept. 9, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action filed on ...
Los Angeles, California--(Newsfile Corp. - September 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharmac...
WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring med...
New York, New York--(Newsfile Corp. - September 8, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc.
Los Angeles, California--(Newsfile Corp. - September 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharmac...
New York, New York--(Newsfile Corp. - August 25, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medi...
- Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter -
Verrica Pharmaceuticals: The Fundamentals Aren't So Clear, But The Stock Chart May Be Telling Us Something
New York, New York--(Newsfile Corp. - July 24, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
– Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates –
– Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development –
New York, New York--(Newsfile Corp. - July 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.
New York, New York--(Newsfile Corp. - July 20, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Verrica Pharmaceuticals, Inc. (N...
Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharmaceuti...
SAN DIEGO & WEST CHESTER, Pa.--(BUSINESS WIRE)---- $VRCA #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc.
New York, New York--(Newsfile Corp. - July 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("Verrica" or...
BENSALEM, Pa.--(BUSINESS WIRE)---- $VRCA #classaction--Law Offices of Howard G.
NEW YORK--(BUSINESS WIRE)-- #VRCA--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Co...
The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Eastern District of P...
– Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information –
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz continues its investigation on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) in...
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agr... [Read more...]
| Industry Biotechnology | IPO Date Jun 15, 2018 |
| CEO Ted White | Employees 29 |
| Stock Exchange NASDAQ | Ticker Symbol VRCA |
Analyst Forecasts
According to 5 analysts, the average rating for VRCA stock is "Strong Buy." The 12-month stock price forecast is 20.83, which is an increase of 53.95% from the latest price.